Leef Brands Inc. (LEEEF)

OTC Pharmaceutical Pharmaceutical Chemicals SIC: 2833
D
Pipeline Grade

Financial Position (from SEC Filings)

$5.8M
Cash & Equivalents
$0.4M
Quarterly Burn Rate
$93M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT07488104 Plantar Pressure and Acceptance of the LEEF-shoe in Individuals With Diabetes-related Neuropathy OTHER Recruiting 30
NCT06971939 Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants PHASE4 Recruiting 285

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for LEEEF.

SEC EDGAR Filings

All SEC filings for Leef Brands Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.